Standard

Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study. / The PRoVENT-COVID Collaborative Group; Steering Committee:; Study coordinators:; Investigators:.

In: Journal of critical care, Vol. 68, 04.2022, p. 31-37.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

The PRoVENT-COVID Collaborative Group, Steering Committee:, Study coordinators: & Investigators: 2022, 'Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study', Journal of critical care, vol. 68, pp. 31-37. https://doi.org/10.1016/j.jcrc.2021.11.009

APA

The PRoVENT-COVID Collaborative Group, Steering Committee:, Study coordinators:, & Investigators: (2022). Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study. Journal of critical care, 68, 31-37. https://doi.org/10.1016/j.jcrc.2021.11.009

Vancouver

The PRoVENT-COVID Collaborative Group, Steering Committee:, Study coordinators:, Investigators:. Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study. Journal of critical care. 2022 Apr;68:31-37. https://doi.org/10.1016/j.jcrc.2021.11.009

Author

The PRoVENT-COVID Collaborative Group ; Steering Committee: ; Study coordinators: ; Investigators:. / Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study. In: Journal of critical care. 2022 ; Vol. 68. pp. 31-37.

BibTeX

@article{11e432eb576149f6a0efac9fd59a6b20,
title = "Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study",
abstract = "Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.",
keywords = "Acute respiratory distress syndrome, COVID-19, Mechanical ventilation, Pulse oximetry, Resource limited settings, SpO/FiO",
author = "Jan-Paul Roozeman and Guido Mazzinari and {Serpa Neto}, Ary and Hollmann, {Markus W.} and Frederique Paulus and Schultz, {Marcus J.} and Luigi Pisani and Algera, {A. G.} and Boers, {L. S.} and Bos, {L. D. J.} and M. Botta and Dongelmans, {D. A.} and Hollmann, {M. W.} and J. Horn and F. Paulus and J. Pillay and Schultz, {M. J.} and Neto, {A. Serpa} and Tsonas, {A. M.} and Vlaar, {A. P. J.} and S. Ahuja and {van Akkeren}, {J. P.} and Algoe, {C. K.} and {van Amstel}, {R. B.} and A. Artigas and Baur, {O. L.} and {van de Berg}, P. and {van den Berg}, {A. E.} and Bergmans, {D. C. J. J.} and {van den Bersselaar}, {D. I.} and Bertens, {F. A.} and Bindels, {A. J. G. H.} and {de Boer}, {M. M.} and {den Boer}, S. and M. Bogerd and Breel, {J. S.} and {de Bruin}, H. and {de Bruin}, S. and Bruna, {C. L.} and Buiteman-Kruizinga, {L. A.} and Cremer, {O. L.} and Determann, {R. M.} and W. Dieperink and Franke, {H. S.} and Galek-Aldridge, {M. S.} and {de Graaff}, {M. J.} and Hagens, {L. A.} and Haringman, {J. J.} and {van der Heide}, {S. T.} and {van der Heiden}, {P. L. J.} and Heijnen, {N. F. L.} and Hiel, {S. J. P.} and Hoeijmakers, {L. L.} and L. Hol and Hoogendoorn, {M. E.} and {van der Horst}, R. and Ie, {E. L. K.} and D. Ivanov and Juffermans, {N. P.} and E. Kho and {de Klerk}, {E. S.} and Gemert, {A. W. M. M. Koopman-van} and M. Koopmans and S. Kucukcelebi and Kuiper, {M. A.} and {de Lange}, {D. W.} and {van Mourik}, N. and Nijbroek, {S. G.} and M. Onrust and Oostdijk, {E. A. N.} and Pennartz, {C. J.} and L. Pisani and Purmer, {I. M.} and Rettig, {T. C. D.} and Roozeman, {J. P.} and Schuijt, {M. T. U.} and Sleeswijk, {M. E.} and Smit, {M. R.} and Spronk, {P. E.} and W. Stilma and Strang, {A. C.} and {The PRoVENT-COVID Collaborative Group} and Tuinman, {P. R.} and Valk, {C. M. A.} and Veen-Schra, {F. L.} and Veldhuis, {L. I.} and {Steering Committee:} and {van Velzen}, P. and {van der Ven}, {W. H.} and {Study coordinators:} and {van Vliet}, P. and {van der Voort}, {P. H. J.} and Investigators: and {van Welie}, L. and Wesselink, {H. J. F. T.} and {van der Wier-Lubbers}, {H. H.} and {van Wijk}, B. and T. Winters and Wong, {W. Y.} and {van Zanten}, {A. R. H.}",
note = "Funding Information: None. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2022",
month = apr,
doi = "10.1016/j.jcrc.2021.11.009",
language = "English",
volume = "68",
pages = "31--37",
journal = "Journal of critical care",
issn = "0883-9441",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study

AU - Roozeman, Jan-Paul

AU - Mazzinari, Guido

AU - Serpa Neto, Ary

AU - Hollmann, Markus W.

AU - Paulus, Frederique

AU - Schultz, Marcus J.

AU - Pisani, Luigi

AU - Algera, A. G.

AU - Boers, L. S.

AU - Bos, L. D. J.

AU - Botta, M.

AU - Dongelmans, D. A.

AU - Hollmann, M. W.

AU - Horn, J.

AU - Paulus, F.

AU - Pillay, J.

AU - Schultz, M. J.

AU - Neto, A. Serpa

AU - Tsonas, A. M.

AU - Vlaar, A. P. J.

AU - Ahuja, S.

AU - van Akkeren, J. P.

AU - Algoe, C. K.

AU - van Amstel, R. B.

AU - Artigas, A.

AU - Baur, O. L.

AU - van de Berg, P.

AU - van den Berg, A. E.

AU - Bergmans, D. C. J. J.

AU - van den Bersselaar, D. I.

AU - Bertens, F. A.

AU - Bindels, A. J. G. H.

AU - de Boer, M. M.

AU - den Boer, S.

AU - Bogerd, M.

AU - Breel, J. S.

AU - de Bruin, H.

AU - de Bruin, S.

AU - Bruna, C. L.

AU - Buiteman-Kruizinga, L. A.

AU - Cremer, O. L.

AU - Determann, R. M.

AU - Dieperink, W.

AU - Franke, H. S.

AU - Galek-Aldridge, M. S.

AU - de Graaff, M. J.

AU - Hagens, L. A.

AU - Haringman, J. J.

AU - van der Heide, S. T.

AU - van der Heiden, P. L. J.

AU - Heijnen, N. F. L.

AU - Hiel, S. J. P.

AU - Hoeijmakers, L. L.

AU - Hol, L.

AU - Hoogendoorn, M. E.

AU - van der Horst, R.

AU - Ie, E. L. K.

AU - Ivanov, D.

AU - Juffermans, N. P.

AU - Kho, E.

AU - de Klerk, E. S.

AU - Gemert, A. W. M. M. Koopman-van

AU - Koopmans, M.

AU - Kucukcelebi, S.

AU - Kuiper, M. A.

AU - de Lange, D. W.

AU - van Mourik, N.

AU - Nijbroek, S. G.

AU - Onrust, M.

AU - Oostdijk, E. A. N.

AU - Pennartz, C. J.

AU - Pisani, L.

AU - Purmer, I. M.

AU - Rettig, T. C. D.

AU - Roozeman, J. P.

AU - Schuijt, M. T. U.

AU - Sleeswijk, M. E.

AU - Smit, M. R.

AU - Spronk, P. E.

AU - Stilma, W.

AU - Strang, A. C.

AU - The PRoVENT-COVID Collaborative Group

AU - Tuinman, P. R.

AU - Valk, C. M. A.

AU - Veen-Schra, F. L.

AU - Veldhuis, L. I.

AU - Steering Committee:

AU - van Velzen, P.

AU - van der Ven, W. H.

AU - Study coordinators:

AU - van Vliet, P.

AU - van der Voort, P. H. J.

AU - Investigators:

AU - van Welie, L.

AU - Wesselink, H. J. F. T.

AU - van der Wier-Lubbers, H. H.

AU - van Wijk, B.

AU - Winters, T.

AU - Wong, W. Y.

AU - van Zanten, A. R. H.

N1 - Funding Information: None. Publisher Copyright: © 2021 The Authors

PY - 2022/4

Y1 - 2022/4

N2 - Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.

AB - Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.

KW - Acute respiratory distress syndrome

KW - COVID-19

KW - Mechanical ventilation

KW - Pulse oximetry

KW - Resource limited settings

KW - SpO/FiO

UR - http://www.scopus.com/inward/record.url?scp=85126317579&partnerID=8YFLogxK

U2 - 10.1016/j.jcrc.2021.11.009

DO - 10.1016/j.jcrc.2021.11.009

M3 - Article

C2 - 34872014

VL - 68

SP - 31

EP - 37

JO - Journal of critical care

JF - Journal of critical care

SN - 0883-9441

ER -

ID: 21245227